Canine gonadal tissues-derived mesenchymal stem cell therapy for early myxomatous mitral valve disease in dogs: the SPRING study, a prospective comparative pilot study

Mesenchymal stem cells (MSCs) are multipotent stromal cells that can promote tissue repair and exert immunomodulatory and anti-inflammatory effects. Myxomatous mitral valve disease (MMVD) is primarily degenerative, and routine pharmacological treatment is not recommended at stage B1. This exploratory study assessed changes in serum transforming growth factor-β1 (TGF-β1) following systemic administration of allogeneic canine gonadal tissue-derived MSCs (GD-MSCs) in client-owned dogs with stage B1 MMVD, with N-terminal pro-B-type natriuretic peptide (NT-proBNP) and echocardiographic measurements as secondary outcomes. The analyzed cohort comprised ten dogs, allocated according to owners’ treatment choices (MSC, n = 5; control, n = 5). Treated dogs received intravenous allogeneic GD-MSCs (1 × 10 6 cells/kg) at monthly intervals for four administrations and were followed for 6 months. Compared with controls, MSC-treated dogs showed greater decreases from baseline to six months in serum TGF-β1 ( p = 0.0317), NT-proBNP ( p = 0.0079), and body weight-normalized anterior mitral leaflet area ( p = 0.0079; Holm- and Bonferroni-adjusted p = 0.0238). The NT-proBNP mean-change difference was − 530.38 pmol/L (Welch 95% confidence interval − 846.19 to − 214.57), although absolute concentrations did not differ significantly between groups at either visit. Changes in body weight-normalized left ventricular end-diastolic internal diameter (LVIDDN) ( p = 0.0397) and vertebral left atrial size (VLAS) ( p = 0.0079) also decreased to a greater extent in the MSC group. GD-MSC administration was associated with six-month changes in circulating biomarkers and selected cardiac imaging measurements in dogs with stage B1 MMVD. These prospective comparative observations support further evaluation of MSCs in early MMVD, with larger randomized studies needed to determine whether the initial signals translate into sustained clinical benefit.

Authors

Publication Details

Journal
BMC Veterinary Research
Published
2026-11-16
DOI
https://doi.org/10.1186/s12917-026-06087-2
Primary Topic
Mesenchymal stem cell research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Canine gonadal tissues-derived mesenchymal stem cell therapy for early myxomatous mitral valve disease in dogs: the SPRING study, a prospective comparative pilot study

So-Young Jeung, Ga‐Hyun Lim, Sung‐Soo Kim, 정유진 et al.
1 links
BMC Veterinary Research
Mesenchymal stem cell research
article

Canine gonadal tissues-derived mesenchymal stem cell therapy for early myxomatous mitral valve disease in dogs: the SPRING study, a prospective comparative pilot study

So-Young Jeung, Ga‐Hyun Lim, Sung‐Soo Kim, 정유진, Sohee Lim, Sun-Hye Song
article en

Abstract

Mesenchymal stem cells (MSCs) are multipotent stromal cells that can promote tissue repair and exert immunomodulatory and anti-inflammatory effects. Myxomatous mitral valve disease (MMVD) is primarily degenerative, and routine pharmacological treatment is not recommended at stage B1. This exploratory study assessed changes in serum transforming growth factor-β1 (TGF-β1) following systemic administration of allogeneic canine gonadal tissue-derived MSCs (GD-MSCs) in client-owned dogs with stage B1 MMVD, with N-terminal pro-B-type natriuretic peptide (NT-proBNP) and echocardiographic measurements as secondary outcomes. The analyzed cohort comprised ten dogs, allocated according to owners’ treatment choices (MSC, n = 5; control, n = 5). Treated dogs received intravenous allogeneic GD-MSCs (1 × 10 6 cells/kg) at monthly intervals for four administrations and were followed for 6 months. Compared with controls, MSC-treated dogs showed greater decreases from baseline to six months in serum TGF-β1 ( p = 0.0317), NT-proBNP ( p = 0.0079), and body weight-normalized anterior mitral leaflet area ( p = 0.0079; Holm- and Bonferroni-adjusted p = 0.0238). The NT-proBNP mean-change difference was − 530.38 pmol/L (Welch 95% confidence interval − 846.19 to − 214.57), although absolute concentrations did not differ significantly between groups at either visit. Changes in body weight-normalized left ventricular end-diastolic internal diameter (LVIDDN) ( p = 0.0397) and vertebral left atrial size (VLAS) ( p = 0.0079) also decreased to a greater extent in the MSC group. GD-MSC administration was associated with six-month changes in circulating biomarkers and selected cardiac imaging measurements in dogs with stage B1 MMVD. These prospective comparative observations support further evaluation of MSCs in early MMVD, with larger randomized studies needed to determine whether the initial signals translate into sustained clinical benefit.

BMC Veterinary Research
Good health and well-being
Mesenchymal stem cell research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon